Lakefront Biotherapeutics (LKFT) Capital Expenditures (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Capital Expenditures for 12 consecutive years, with -$139968.4 the latest figure, recorded in Q1 2026.

• Quarterly Capital Expenditures rose 97.59% year-over-year to -$139968.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.3 million (up 21.53% YoY) and the FY2025 annual result came in at $15.6 million, down 18.04% from the prior year.
• Capital Expenditures eased to -$139968.4 in Q1 2026 per LKFT's latest filing, from $29.4 million in the prior quarter.
• Over the last five years, Capital Expenditures for LKFT reached as high as $53.7 million in Q4 2022 and fell as low as -$10.4 million in Q1 2022.
• A 5-year average of $8.2 million and a median of -$3.8 million in 2024 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures slumped 36.9% — and 2026, when it soared 97.59%.
• Year by year, Capital Expenditures stood at $53.7 million in 2022, then sank by 36.9% to $33.9 million in 2023, then declined by 5.91% to $31.9 million in 2024, then dropped by 7.91% to $29.4 million in 2025, then sank by 100.48% to -$139968.4 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$139968.4, $29.4 million, and -$3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.